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A Subset of Methylated CpG Sites Differentiate
Psoriatic from Normal Skin
Elisha D.O. Roberson1,5, Ying Liu1,5, Caitriona Ryan2, Cailin E. Joyce1, Shenghui Duan1, Li Cao1,
Ann Martin3, Wilson Liao4, Alan Menter2 and Anne M. Bowcock1,3
Psoriasis is a chronic inflammatory immune-mediated disorder affecting the skin and other organs including
joints. Over 1,300 transcripts are altered in psoriatic involved skin compared with normal skin. However, to our
knowledge, global epigenetic profiling of psoriatic skin is previously unreported. Here, we describe a genome-
wide study of altered CpG methylation in psoriatic skin. We determined the methylation levels at 27,578CpG
sites in skin samples from individuals with psoriasis (12 involved, 8 uninvolved) and 10 unaffected individuals.
CpG methylation of involved skin differed from normal skin at 1,108 sites. Twelve mapped to the epidermal
differentiation complex, upstream or within genes that are highly upregulated in psoriasis. Hierarchical
clustering of 50 of the top differentially methylated (DM) sites separated psoriatic from normal skin samples
with uninvolved skin exhibiting intermediate methylation. CpG sites where methylation was correlated with
gene expression are reported. Sites with inverse correlations between methylation and nearby gene expression
include those of KYNU, OAS2, S100A12, and SERPINB3, whose strong transcriptional upregulation is an
important discriminator of psoriasis. Pyrosequencing of bisulfite-treated DNA from skin biopsies at three DM
loci confirmed earlier findings and revealed reversion of methylation levels toward the non-psoriatic state after
1 month of anti-TNF-a therapy.
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INTRODUCTION
Psoriasis is a chronic, relapsing inflammatory skin disease
affecting approximately 2% of the US population and 125
million people worldwide (Bowcock and Krueger, 2005;
Gudjonsson et al., 2010; Suarez-Farinas et al., 2010). It is a
lifelong disease presenting predominantly before the age of
40, with spontaneous remissions infrequent. Flares can be
exacerbated by stress, infection, medications, or other
environmental triggers (Langley et al., 2005). In psoriasis,
immune cell activation and altered epidermal differentiation
are key pathogenic events (Lew et al., 2004; Zaba et al.,
2009), and these are correlated with major changes in the
transcriptome (Bowcock et al., 2001; Nomura et al., 2003;
Zhou et al., 2003; Quekenborn-Trinquet et al., 2005;
Mee et al., 2007; Gudjonsson et al., 2010; Suarez-Farinas
et al., 2010).
Epigenetic alterations such as DNA methylation and
histone modification are correlated with gene expression
changes (Reik, 2007; Champagne and Curley, 2009; Shi and
Wu, 2009; Wilson et al., 2009). Such alterations may be part
of normal developmental or differentiation processes but can
also be triggered by environmental factors (Santos and Dean,
2004; Morgan et al., 2005; Weber et al., 2005; Eckhardt
et al., 2006; Suter and Aagaard-Tillery, 2009). In mammals,
DNA methylation commonly occurs at CpG dinucleotides
(Bestor and Coxon, 1993). Approximately 70–80% of the
CpG dinucleotides in the human genome are methylated,
predominately in areas harboring repetitive sequences (Bird,
2002). However, regions rich in CpGs, termed CpG islands,
are also found in promoters of more than 70% of annotated
genes (Bird et al., 1985; Saxonov et al., 2006). Approximately
half of the CpG islands are associated with annotated gene
transcription start sites (Bird, 2002), whereas others can have
discrete sets of CpG sites within their promoters. The
methylation of these sites has direct effects on transcriptional
levels, where methylation levels typically demonstrate an
inverse correlation with expression level (Bell et al., 2011).
There have been only a few studies of epigenetic
alterations in diseased tissue. Many of these have involved
cancerous tissue where the methylation status of tumor
genomes are compared with matched normal tissue
(Hu et al., 2005; Ordway et al., 2006; Irizarry et al., 2009;
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Koga et al., 2009). Studies of methylation changes in the
diseased tissues of patients with complex diseases, including
those leading to autoimmunity, are limited as diseased tissue
is often difficult to access. A study on epigenetic changes in
the blood of systemic lupus erythematosus patients revealed
altered methylation of several genes contributing to T-cell
autoreactivity, B-cell overstimulation, and macrophage kill-
ing (Strickland and Richardson, 2008). Psoriasis has an
advantage over many autoimmune diseases because of the
accessibility of its main target organ: the skin. There have
been a few reports of altered methylation within promoters of
single genes in diseased skin. One example is the SHP-1
(PTPN6) promoter, which is reported to be demethylated in
psoriatic skin but not in skin from atopic dermatitis patients or
healthy controls (Ruchusatsawat et al., 2006). However,
genome-wide studies of methylation changes in psoriasis, to
our knowledge, have not been previously described.
Here we describe global changes of methylation in
involved psoriatic skin (PP) versus uninvolved psoriatic (PN)
and normal (NN) skin. This was performed by querying
27,578CpG sites with Illumina bead arrays with DNA
derived from samples of each skin type. Many differences
between PP versus NN skin were seen. Hierarchical
clustering of 50 of the top differentially methylated (DM)
sites demonstrated excellent power for differentiating PP
versus NN skin. We also identified a subset of CpG sites in
which methylation was correlated with gene expression.
Intermediate methylation at DM CpG sites was seen in PN
skin, suggesting inherent epigenetic differences. Querying a
subset of DM sites with an independent approach (pyrose-
quencing of bisulfite-treated DNA) confirmed the DM
detected with the Illumina bead arrays, and also demon-
strated that anti-TNF-a treatment in responders partially
restores normal CpG methylation status at these loci.
RESULTS
Differential CpG site methylation in psoriatic skin
We used the high-throughput genome-wide bead array
(Infinium HumanMethylation27 Beadchip, Illumina, San Diego,
CA) to obtain a global, quantitative measure of the methyla-
tion status of CpG sites in PP, PN, and NN skin (GSE31835).
The array spanned 27,578CpG loci selected from more than
14,000 genes, including more than 1,000 cancer-related genes
and the promoter regions of 110 miRNAs. The vast majority of
assayed CpG sites were located in the promoter regions of their
cognate genes with an average distance of 365bp (maximum
B1.5 kb) from their transcription start sites.
PP skin samples were defined as skin biopsies collected
from the site of an active psoriatic lesion. Conversely, PN skin
samples were biopsies collected from skin that showed
no evidence of macroscopic change. All psoriasis patient
samples were collected at least 4 weeks after discontinuation
of all systemic or topical therapy. Psoriasis Area and Severity
Index (PASI) scores for psoriasis patients generally ranged
from 410 to 30%. NN skin biopsies were defined as those
biopsies collected from healthy volunteers with no clinically
evident skin lesions and no self-reported history of psoriatic
outbreaks. Our study included 12 PP, 8 PN, and 10 NN skin
samples. The PN samples were derived from donors who also
contributed a PP sample; hence, there were eight ‘‘paired’’
PP/PN samples and four additional PP samples without a
matched PN sample.
The workflow used for analysis of the methylation data is
presented in Supplementary Figure S1 online. For each CpG
target on each array, we calculated both percent methylation
(b-value) and a methylation log ratio (M-value; Methods;
Supplementary Figures S1 and S2 online). TheM-values were
used for tests of differential methylation, as their standard
deviations are more stable across a range of mean intensities
than those of b-values (Supplementary Figure S3 online; Du
et al., 2010).
We defined a CpG as DM if it had a false-discovery rate-
corrected P-value less than our significance threshold of 0.05
(Supplementary Figure S1 online). CpG methylation in PP
versus NN skin differed at 1,108CpG sites, 88 of which
demonstrated a greater than 2-fold change in M-value
(Figure 1; Supplementary Table ST1 online). The top DM
sites for this comparison are shown in Table 1. A total of
27CpG sites demonstrated differential methylation in PP skin
compared with PN skin from the same individual, and two of
those sites had a greater than twofold change in the M-value
(Figure 1; Supplementary Table ST2 online). Interestingly, PN
skin compared with NN skin was DM at 15CpGs, eight of
which had a greater than twofold change in the M-value
(Figure 1; Supplementary Table ST3 online). Additional loci
may be discovered in follow-up studies with more samples in
each group (Supplementary Figure S4 online).
A total of 96 genes had at least two CpG sites in their
vicinity, where methylation levels were significant in the PP
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Figure 1. Venn diagram of the CpG sites exhibiting differential methylation
for each of three contrasts, with a significance cutoff of 0.05 for the adjusted
P-value. The contrasts are PP compared with PN (paired t-test), PP compared
with NN, and PN compared with NN. For each set, the upper number is a
count of the number of CpG sites with increased methylation, and the lower
number is the count of CpG sites with decreased methylation. The total count
of unique sites showing increased or decreased methylation in at least one
comparison is shown at the bottom right.
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versus NN comparisons. CCND1 and GATA4 had four
significant sites each, whereas GPX3 and SFRP4 had three
significant sites each. The most extreme change was found in
cg16139316, which lies upstream from S100A9 (P-value
o0.00001) within the epidermal differentiation complex, a
region key to epidermal development (Volz et al., 1993). For
this CpG site, methylation levels were 6.97-fold decreased
in PP versus NN skin. S100A9 is strongly upregulated in
psoriatic skin (Semprini et al., 2002; Broome et al., 2003;
Zhou et al., 2003; Benoit et al., 2006; Suarez-Farinas et al.,
2010), and the decreased methylation in psoriatic skin is
consistent with its enhanced expression. In total, there were
12 CpG sites from the epidermal differentiation complex
whose methylation levels were decreased in PP versus NN
and which mapped close to genes upregulated in psoriasis
(S100A3, S100A5, S100A7, S100A12, SMCP, SPRR2A,
SPRR2D, SPRR2E, LCE3A; Figure 2a).
The largest number of methylation differences and the
differences of the largest magnitude were seen in the PP
versus NN comparison (Supplementary Table ST1 online).
There were comparatively few methylation changes in PP
versus PN. These data contrast with expression analyses in
which the PP versus PN skin comparisons are similar to the
PP versus NN comparisons, although this may be an effect of
small sample size (Zhou et al., 2003; Gudjonsson et al.,
2010). The largest fold methylation increase in PP versus PN
skin was in sites upstream from MCF.2 cell line-derived
transforming sequence-like (MCF2L; FC¼ 2.40) and laminin
alpha 4 (LAMA4; FC¼2.58). The largest fold decreases were
in sites upstream from synaptopodin (SYNPO; FC¼1.91)
and bone marrow stromal cell antigen 2 precursor (BST2;
FC¼1.76). Although the changes in methylation were
significant, none of these genes have demonstrated differ-
ential expression in psoriasis.
Methylation differences in PN compared with NN skin
were similarly few in number. The greatest fold changes (X2)
were all increases in methylation in PN versus NN skin.
These included sites near GALR1, ZNF454, ZNF540, NEF3,
RGS7, MLF1, FLJ42486, and NRIP2 (Supplementary Table
ST3 online). MLF1 transcripts are downregulated in psoriasis,
consistent with the increase in methylation (Suarez-Farinas
et al., 2010), but, to our knowledge, none of the other genes
have been described as differentially expressed in psoriatic
skin. The greatest decrease in methylation (1.81-fold) was
in a CpG site approximately 500 bp upstream of the
ZDHHC12 promoter.
Methylation levels correctly classify involved, uninvolved, and
normal skin samples
We hypothesized that methylation levels of DM CpG sites
could be used to classify the different skin groups. We
performed between-group analyses with principal compo-
nent metrics and identified a subset of 50 sites (25 with
increased methylation, 25 with decreased methylation) that
differentiated PP from NN skin (Supplementary Table ST4
online). Data on an additional seven PP samples were
obtained for cross-validation of clustering validity.
A heat map of normalized M-values at the top 50
differentiating sites was generated with all PP, PN, and NN
samples (Figure 2b). The hierarchical clustering of these sites
demonstrated excellent classifying power (Supplementary
Table ST5 online). Classifications of psoriatic (PP or PN)
versus NN were 100% accurate and 100% specific. PP
clustered separately from both PN and NN skin, and
performed well, with 100% sensitivity and 90% specificity.
PN was classified with 75% sensitivity and 100% specificity.
The lower sensitivity for PN samples was due to two PN
samples (PN4, PN5) being classified as PP. On the basis of
this data set, the classifying power of the global methylation
data performed very well, especially at the classification of PP
versus NN skin, and may be as good a predictor of psoriasis
as gene expression values.
Table 1. The top 10 most significant CpG sites with differential methylation in PP versus NN skin
Raw b-values
ID Symbol Relevant GO BP term summary Chrom. Position_hg18 FDR P-value PP NN
cg03699566 FOLR1 Cell death 11 71,578,300 5.89E06 0.66±0.04 0.43±0.03
cg11668844 MCF2L Apoptosis 13 112,703,623 5.89E06 0.45±0.04 0.26±0.02
cg16139316 S100A9 Chronic inflammation 1 151,597,382 5.89E06 0.46±0.08 0.84±0.01
cg04126866 C10orf99 — 10 85,922,743 8.04E06 0.65±0.04 0.85±0.01
cg02813121 S100A12 Immune response, positive regulation of NF-kB cascade 1 151,615,535 1.17E05 0.72±0.02 0.82±0.01
cg06131859 KYNU Response to IFN-g 2 143,351,601 1.17E05 0.32±0.04 0.58±0.03
cg17582777 EFNA3 Cell–cell signaling 1 153,316,724 1.58E05 0.79±0.02 0.68±0.02
cg13210534 HSPB2 Response to unfolded protein 11 111,289,538 2.22E05 0.41±0.02 0.33±0.02
cg20161089 IFI27 Apoptosis, type 1 IFN signaling 14 93,647,267 2.49E05 0.4±0.04 0.63±0.02
cg16142218 CHMP7 Cell membrane organization, endosome transport 8 23,157,166 4.55E05 0.29±0.04 0.45±0.03
Abbreviations: BP, biological process; Chrom., chromosome; FDR P-value, false-discovery rate-corrected P-value; GO BP term, Gene Ontology biological
process; ID, Illumina CpG ID; NN, normal; PP, psoriatic.
b-Values approximate percent DNA CpG methylation.
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Figure 2. Epidermal differentiation complex (EDC) methylation and classification of sample group by clustering. (a) Differentially methylated CpGs that
map to the EDC. Genes of the EDC are critical to epidermal development.Twelve differentially methylated CpG sites in PP compared with NN map to this
region of chromosome 1. Shown are these sites and the nearby genes with chromosome ideogram. The image was adapted from a postscript generated
with the UCSC genome browser (Fujita et al., 2010). (b) Heat map showing PP, PN, and NN samples clustered with the top 50CpG sites that differentiate
PP from NN skin. Image was generated with normalized M-values. Red values indicate relatively increased methylation, whereas green indicates relatively
decreased methylation.
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Uninvolved skin exhibits intermediate levels of differential
CpG methylation
We prepared box plots of the top 50 sites, separated by the
direction of the methylation change observed in PP versus
NN skin and by sample group. The medians of the three
groups for sites with increased and decreased methylation
were significantly different by the Kruskal–Wallis rank sum
test. The trend is apparent for both the raw b-values and the
normalized M-values (Supplementary Table ST4 online). We
also observed that PN skin had a methylation level
intermediate to that of the NN and PP skin for these top
50 sites (Figure 3). These intermediate methylation levels
contrast with the expression levels of mRNA transcripts in PN
skin, which for many transcripts are usually very similar to
that of normal skin (Bowcock et al., 2001). These differences
may indicate intrinsic epigenetic differences in PN versus NN
skin, which may be reflective of a predisposition to psoriasis.
However, the smaller differences in CpG methylation of PP
versus PN skin suggest that the number of samples available
might have been too low (under-powered) to detect some of
these alterations.
Correlation of methylation with gene expression
Nine PP, five PN, and six NN samples used for methylation
analysis had also been used for global transcriptome analysis
with the Affymetrix U95 arrays (Zhou et al., 2003). We were
therefore able to perform a direct correlation between
methylation at specific CpG loci and the level of expression
of a downstream gene for these samples.
Correlations between methylation score values and gene
expression levels were performed with R, and P-values were
reported on the basis of an false-discovery rate-corrected
P-value cutoff of 0.05. There were 12 CpG sites at which
methylation levels correlated significantly with gene expres-
sion levels at a nearby locus (adj. P-value p0.05; Supple-
mentary Table ST6 online). Among these sites, nine
demonstrated negative correlations with nearby genes:
C10orf99, OAS2 (3 sites), LGALS3BP, KYNU, IL1B, TRIM22,
and PHYHIP. Three demonstrated positive correlations with
nearby genes: GDPD3, TRIM14, and CCND1. Many of the
genes that demonstrated a negative correlation between
expression and methylation are highly upregulated in
psoriasis (C10orf99, OAS2, LGALS3BP, KYNU, IL1B,
TRIM22; Zhou et al., 2003), providing evidence of underlying
methylation changes in the highly upregulated genes in
PP skin.
Overall, relatively few genes showed correlation between
methylation status and gene expression. There are two
possibilities for this. First, the expression data used from
previous generation expression arrays had fewer elements,
covered fewer genes, and had less dynamic range than most
modern arrays. A second reason may be low sample sizes
(PP, n¼9; PN, n¼ 5; NN, n¼6), which might have contri-
buted to a lack of power to detect expression/methylation
correlations. Therefore, rather than directly correlating
expression and methylation for the same samples, we
pursued a separate approach: A consensus list of 890
downregulated and 732 upregulated genes in psoriatic skin
determined across expression studies was recently described
(Suarez-Farinas et al., 2010). When this list was intersected
with our methylation data, 128 DM CpG sites in PP
compared with NN were less than 1.5 kilobases from the
transcription start site of 113 genes in that consensus list
(Supplementary Tables ST1–3 online). For example, the genes
CCL27, DDAH2, TNS1, and TRIM2 all showed consistent
downregulation in psoriatic skin, and we found consistently
increased methylation in and near these genes. By contrast,
IFI27, KYNU, OAS2, S100A9, SERPINB3, and TNIP3 all
showed significantly increased expression in psoriasis, and
we found significantly decreased methylation for sites near
them. There was only one gene in the consensus set in which
decreased expression correlated with decreased methylation:
FCGBP is significantly downregulated in psoriatic lesions, but
we found significantly decreased CpG methylation approxi-
mately 430 bp upstream of this gene at cg19103704.
Fine mapping of differential methylation by pyrosequencing and
response to treatment with a TNFa inhibitor
We targeted three regions for further methylation analyses.
Each of these had exhibited a difference in CpG methylation
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Figure 3. Box plots of methylation levels in three sample groups. Shown are
two box plots of normalized M-value versus the sample group (NN, PN, PP).
Displayed P-values were derived from the non-parametric Kruskal–Wallis test
for equality of medians among groups. Dark lines represent the median of
each group. The bottom and top borders of each box are defined by the first
and third quartiles. Whiskers reach out to data points up to 1.5 times the
interquartile range above or below the appropriate quartile. Data points
outside of that range are considered outliers and are represented by
circles. (a) Methylation M-values for top 25 sites that show increased
methylation. (b) Methylation M-values for top 25 sites that show decreased
methylation.
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in PP skin compared with NN skin (C10orf99¼1.35;
IFI27¼2.74; SERPINB4¼1.44). We used pyrosequen-
cing as a separate approach to confirm these methylation
differences and to investigate additional CpG sites within the
c10orf99 and IFI27 intervals. In all cases, the original CpG
site determined to be DM with the Illumina bead array was
included in the pyrosequencing assay, along with nearby
CpG sites. For all of these loci, the NN and PN samples
demonstrated greater methylation than that seen in the PP
samples (Figure 4). Many of these differences were statistically
significant. Hence, we confirmed the differential methylation
between PP and NN and/or PN skin detected by methylation
bead arrays, and also showed that additional CpG sites in the
DM regions exhibited similar methylation trends.
We also had access to PP skin biopsies from five psoriasis
patients who were being treated with the anti-TNF-alpha
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monoclonal antibody adalimumab (Humira). The standard
dosing of 80mg was applied by subcutaneous injection at
week 0, 40mg subcutaneous at week 1, and thereafter 40mg
subcutaneous every other week (Menter et al., 2008).
Characteristics of the patients, including age, sex, and PASI
score over time, were ascertained for these patients (Supple-
mental Table ST7 online).
We obtained skin biopsies from these patients before
treatment and after 1 month of adalimumab (post treatment).
The pre-treatment biopsies were taken from within a psoriatic
plaque, and the post-treatment biopsies were taken either
adjacent to the original biopsy site or from a resolving
psoriatic plaque contralateral to the original biopsy site. Four
out of five patients responded well to the adalimumab
treatment and achieved a greater than 75% improvement in
the PASI score (PASI-75) at 6 months (ST7). Pyrosequencing
at the same loci described above was also performed on the
pre- and post-treatment samples. At 1 month, plaques had not
completely resolved. However, at each locus we observed
that the mean methylation levels of treated samples
increased, becoming more similar to that of uninvolved skin,
although the difference was only statistically significant at
CpG1 of C10orf99 (Figure 4). This suggests that methylation
assays at a discrete set of loci might be a useful way to predict
treatment response early in treatment.
DISCUSSION
To our knowledge, global CpG methylation changes in
psoriatic versus normal skin have not previously been
reported. We observed extensive differences in global
methylation in PP skin compared with NN. These observa-
tions are similar to those we and others have made following
expression comparisons of the same skin types (Bowcock
et al., 2001; Oestreicher et al., 2001; Suomela et al., 2004;
Gudjonsson et al., 2010; Suarez-Farinas et al., 2010). We
identified a subset of DM CpG sites that correlated
significantly with the differential expression of nearby genes.
Many of these genes are highly upregulated in psoriasis and a
number map to the epidermal differentiation complex. Some
of the highly upregulated genes, such as KYNU, OAS2,
S100A12, and SERPINB3, are members of a set of genes
whose high expression level differentiates psoriasis from
other inflammatory skin diseases such as atopic dermatitis
(Guttman-Yassky et al., 2009). Hence, altered CpG methyla-
tion near genes such as these is expected to be a good
predictor of the psoriatic state. Many of the genes with the
greatest methylation differences are expressed by keratino-
cytes. This is similar to the major alterations in mRNA levels
from psoriatic versus normal skin (Bowcock et al., 2001;
Nomura et al., 2003; Zhou et al., 2003; Quekenborn-
Trinquet et al., 2005; Mee et al., 2007; Gudjonsson et al.,
2010; Suarez-Farinas et al., 2010). Psoriatic blood has limited
expression changes compared with blood from healthy
controls (Lee et al., 2009), and we would expect similar
findings from an investigation of methylation alterations in
this tissue.
We also identified methylation differences between PP
compared with PN skin, as well as between PN compared
with NN skin. However, the number of DM sites in the PP
versus PN comparisons was not nearly as great as those
identified in the PP versus NN comparisons. This contrasts
with expression studies in which PP versus NN and PP versus
PN comparisons yield some of the greatest alterations in
transcript levels. In fact, PN skin frequently exhibited
methylation levels that were intermediate with respect to
PP and NN skin. This might be due to tissue heterogeneity in
the PN skin, but this difference, to our knowledge, has not
been seen with expression studies. This observation needs to
be explored further.
Although we observed correlations (primarily inverse
relationships) between CpG methylation and expression of
nearby genes, a significant number of DM CpG sites did not
exhibit correlation with expression. This might be because of
limited power based on the number of samples studied.
Moreover, some DM genes might be expressed at low levels
and have been missed by hybridization-based microarray
analysis. In these instances, non-hybridization strategies,
such as RNA sequencing (RNA-Seq), may provide insight
into less abundant transcripts in psoriasis. In other instances,
these methylation differences might reflect altered methyla-
tion of noncoding RNAs, long-range regulatory elements such
as enhancers (Yoon et al., 2005; Brideau et al., 2010;
Lujambio et al., 2010; Shore et al., 2010; Hoivik et al., 2011),
or even elements mediating intra-chromosomal effects (Sharp
et al., 2010).
It is unclear at this stage whether the epigenetic differences
described here are secondary to the altered signaling
pathways of psoriasis, or are a stable predisposing event
within psoriatic skin. A precedence for altered methylation
predisposing to activation of the immune system is reported
for interleukin-2, where demethylation at a specific CpG site
in its promoter is associated with its transcriptional upregula-
tion in mice and humans (Bird, 2003; Bruniquel and
Schwartz, 2003). This demethylation induces recruitment of
Oct-1 and changes in histone modifications. Oct-1 remains
on the enhancer region in a stable manner and leads to a
faster and stronger induction upon subsequent stimulation.
Hence, altered DNA methylation functions as a memory of
the regulatory event (Murayama et al., 2006), and it is
possible that similar types of epigenetic memory exist in
psoriatic skin.
Multiple clinical trials have demonstrated the efficacy of
TNF blockade for the treatment of psoriasis (Menter et al.,
2007, 2008). When we examined the effect of adalimumab
(Sladden et al., 2005) on global CpG methylation, we
observed that after a month of treatment methylation levels
had changed in the direction seen in uninvolved skin. Hence,
although altered methylation in psoriatic versus normal skin
is not unexpected, the fact that it can be a surrogate for gene
expression, together with the relative ease with which it can
be assayed, makes it attractive as a possible predictor for
diagnosing the status of activity in psoriatic skin, particularly
when RNA from samples is inaccessible. Similarly, treatment
response and remissions may be predicted, offering the
opportunity to discontinue therapy for periods of time with
significant cost saving to the patient.
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MATERIALS AND METHODS
Skin biopsy samples
The study was conducted according to the Declaration of Helsinki
Principles. Punch biopsies (3 to 6 mm) were obtained from the PP
and PN skin of psoriasis patients and NN skin from healthy controls
(Supplementary Table ST8 online). The transcriptomes of some of
these samples were previously analyzed and are described else-
where (Bowcock et al., 2001; Zhou et al., 2003). Skin biopsies were
obtained from collaborating dermatologists at the Washington
University School of Medicine (Saint Louis, MO), Psoriasis clinic,
Baylor Hospital (Dallas, TX), or from the University of California in
San Francisco (CA). Informed written consent was obtained from all
individuals who donated skin biopsies. Protocols for obtaining
patient biopsies were approved by Institutional Review Boards for
the protection of human subjects.
DNA methylation profiling with Illumina bead arrays
Qiagen DNeasy Kits were used to isolate genomic DNA from skin
biopsy samples according to the manufacturer’s instructions. All
samples were analyzed for DNA integrity, purity, and concentration
on a Nanodrop Spectrophotometer DN-100 (Nanodrop Technol-
ogies, Wilmington, DE). Bisulfite DNA conversion was performed by
using the EZ DNA methylation kit (Zymo Research, Irvine, CA)
according to the manufacturer’s recommendations (Bibikova et al.,
2006). Bisulfite-converted genomic DNA was then interrogated
with the Illumina Infinium HumanMethylation27 Beadchip, with
the recommended protocols provided by the manufacturer. After
hybridization, the arrays were imaged with a BeadArray Reader
scanner. Image processing, intensity data extraction, and analyses
were conducted with the BeadArray Reader.
Differential methylation analysis
Non-normalized methylation data were analyzed with the R (v2.12.
0) Bioconductor (Biobase v2.10.0) methylumi (v1.4.0) and lumi
(v2.2.0) packages (Gentleman et al., 2004; Du et al., 2008; Davis
et al., 2010; R Development Core Team, 2010). Supplementary
Figure S1 online provides a description of the workflow used for
statistical analyses. Color channel intensities within each array were
quantile normalized with the ‘‘lumiMethyC’’ function, and data
were globally normalized between arrays with simple scaling
normalization via the ‘‘lumiMethyN’’ function. In some tables, we
report b-values and M-values. b-Values are intuitive, and M-values
were used for statistical tests. Let the intensity of the methylated and
unmethylated alleles be Imeth and Iunmeth, respectively.
b-Value calculation (percent methylation): b ¼ ImethImethþIunmeth
M-value calculation (methylation ratio): M ¼ log2 ImethIunmeth
 
Limma (v3.6.6) was used to fit linear models to each CpG
(detection P-value p0.01 in at least one sample; Smyth, 2005).
Contrasts were defined for PP versus NN and PN versus NN. The log
odds of differential methylation were calculated for each CpG in
each contrast with the ‘‘eBayes’’ function.
Paired PP/PN samples were treated as paired samples. Linear
models were fitted to only these samples, and the ‘‘eBayes’’ function
was used to calculate the moderated paired t-test. All P-values were
adjusted for multiple tests with the false-discovery rate method
(Benjamini and Hochberg, 1995). Supplemental power calculations
were performed in R 2.12.0 (Champely, 2009).
Selection of the top-50 group discriminating DM CpG sites
Between-group analysis was used to determine CpG sites that
most differentiate PP from NN skin. Between-group analysis of PP
versus NN was performed using M-values for DM CpG sites
with the ‘‘bga’’ function of the MADE4 R package (Culhane et al.,
2002, 2005). The discriminating method used was principal
components analysis. The sites were selected as the top 25 increased
and top 25 decreased methylation sites on the first principal
component axis. The top 50 sites were subsequently used to
generate heat maps showing the discriminatory power of these sites
with Euclidean distance measures and complete hierarchical
clustering. Heat maps were generated with the Heatplus R package
(v1.20.0) with a 50-color palette from the marray package maPalette
function (v1.28.0).
Correlation with gene expression
Pearson’s correlation coefficients and their 95% confidence intervals
were calculated to evaluate the strength of linear dependence
between methylation at specific CpG loci and the level of expression
of a downstream target. The false-discovery rate-adjusted P-values
were calculated to test the null hypothesis of zero correlation.
All analyses were performed with the R statistical programming
language (v2.10.1).
Pyrosequencing
CpG methylation at and around sites flanking the statistically
significant Illumina CpG loci were further validated with pyrose-
quencing of bisulfite-treated DNA. This allowed us to quantify
methylation at multiple CpG sites individually (Colella et al., 2003).
Sample bisulfite treatment, PCR amplification, pyrosequencing, and
extraction of percent methylation were performed at EpigenDx
(Worcester, MA). Loci analyzed were promoter regions of IFI27,
SERPINB4, and C10orf99 genes.
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